Factor XIII subunits in human tears; their highly elevated levels following penetrating keratoplasty

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 271-276

  Orosz, Zsuzsanna Z ^a   Katona, Éva ^a   Facskó, Andrea ^a   Módis, László ^a   Muszbek, László ^a,b   Berta, András ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Corneal transplantation; Factor XIII; Neovascularization; Penetrating keratoplasty; Tears; Wound healing

Indexed keywords

BLOOD CLOTTING FACTOR 13 A2B2; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 13B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; CORNEA ULCER; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KERATOCONUS; KERATOPATHY; LACRIMAL FLUID; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; SCAR; VOLUNTEER; WOUND HEALING;

ADULT; AGED; CASE-CONTROL STUDIES; FACTOR XIII; FEMALE; HUMANS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; PROTEIN SUBUNITS; TEARS; YOUNG ADULT;

EID: 78650236127     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.10.017     Document Type: Article

References (43)

1. Schuster V., Hugle B., Tefs K. Plasminogen deficiency. J Thromb Haemost 2007, 5:2315-2322.
2. Mehta R., Shapiro A.D. Plasminogen deficiency. Haemophilia 2008, 14:1261-1268.
3. Drew A.F., Kaufman A.H., Kombrinck K.W., et al. Ligneous conjunctivitis in plasminogen-deficient mice. Blood 1998, 91:1616-1624.
4. Tozser J., Berta A. Urokinase-type plasminogen activator in rabbit tears. Comparison with human tears. Exp Eye Res 1990, 51:33-37.
5. Pandolfi M., Astedt B., Dyster-Aas K. Release of fibrinolytic enzymes from human cornea. Acta Ophthalmol (Copenh) 1972, 50:199-205.
6. Rijken D.C., Wijngaards G., Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981, 97:477-486.
7. Hayashi K., Sueishi K. Fibrinolytic activity and species of plasminogen activator in human tears. Exp Eye Res 1988, 46:131-137.
8. Williams D.L., Risse B., Kim S., et al. Plasminogen activator inhibitor type 2 in human corneal epithelium. Investig Ophthalmol Vis Sci 1999, 40:1669-1675.
9. Csutak A., Silver D.M., Tozser J., et al. Plasminogen activator inhibitor in human tears after laser refractive surgery. J Cataract Refract Surg 2008, 34:897-901.
10. Kao W.W., Kao C.W., Kaufman A.H., et al. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice. Investig Ophthalmol Vis Sci 1998, 39:502-508.
11. Muszbek L., Bagoly Z., Bereczky Z., Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008, 6:190-205.
12. Muszbek L., Yee V.C., Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999, 94:271-305.
13. Duckert F., Jung E., Shmerling D.H. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960, 5:179-186.
14. Ivaskevicius V., Seitz R., Kohler H.P., et al. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007, 97:914-921.
15. Karimi M., Bereczky Z., Cohan N., Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost 2009, 35:426-438.
16. Inbal A., Lubetsky A., Krapp T., et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost 2005, 94:432-437.
17. Dardik R., Loscalzo J., Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006, 4:19-25.
18. Dardik R., Solomon A., Loscalzo J., et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003, 23:1472-1477.
19. Dardik R., Loscalzo J., Eskaraev R., Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005, 25:526-532.
20. Dardik R., Krapp T., Rosenthal E., Loscalzo J., Inbal A. Effect of FXIII on monocyte and fibroblast function. Cell Physiol Biochem 2007, 19:113-120.
21. Orosz Z.Z., Katona E., Facsko A., Berta A., Muszbek L. A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. J Immunol Meth 2010, 353:87-92.
22. Berta A. Standardization of tear protein determination: the effects of sampling, flow rate and vascular permeability. The precorneal tear film in health, disease and contact lens wear 1986, 418-435. Dry Eye Institute, Lubbock TX. F. Holly (Ed.).
23. Katona E.E., Ajzner E., Toth K., Karpati L., Muszbek L. Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Meth 2001, 258:127-135.
24. Katona E., Haramura G., Karpati L., Fachet J., Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost 2000, 83:268-273.
25. Yorifuji H., Anderson K., Lynch G.W., Van de Water L., McDonagh J. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988, 72:1645-1650.
26. Wilkinson K.D. Quantitative analysis of protein-protein interactions. Meth Mol Biol 2004, 261:15-32.
27. Tiffany J.M. The normal tear film. Dev Ophthalmol 2008, 41:1-20.
28. Hingorani M., Metz D., Lightman S.L. Characterisation of the normal conjunctival leukocyte population. Exp Eye Res 1997, 64:905-912.
29. Perrio M.J., Ewen D., Trevethick M.A., Salmon G.P., Shute J.K. Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins. Clin Exp Allergy 2007, 37:1688-1700.
30. Berta A. Enzymology of the tears 1992, CRC Press, Boca Raton. 0 ed.
31. Fullard R.J., Snyder C. Protein levels in nonstimulated and stimulated tears of normal human subjects. Investig Ophthalmol Vis Sci 1990, 31:1119-1126.
32. Fullard R.J., Tucker D.L. Changes in human tear protein levels with progressively increasing stimulus. Investig Ophthalmol Vis Sci 1991, 32:2290-2301.
33. Brackmann H.H., Egbring R., Ferster A., et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995, 74:622-625.
34. Fear J.D., Miloszewski K.J., Losowsky M.S. The half life of factor XIII in the management of inherited deficiency. Thromb Haemost 1983, 49:102-105.
35. Rodeghiero F., Tosetto A., Di Bona E., Castaman G. Clinical pharmacokinetics of a placenta-derived factor XIII concentrate in type I and type II factor XIII deficiency. Am J Hematol 1991, 36:30-34.
36. Mishima S., Gasset A., Klyce S.D., Baum J.L. Determination of tear volume and tear flow. Investig Ophthalmol 1966, 5:264-276.
37. Mathers W.D., Daley T.E. Tear flow and evaporation in patients with and without dry eye. Ophthalmology 1996, 103:664-669.
38. Schuller S., Knorr M., Steuhl K.P., Thiel H.J. Lacrimal secretion of human epidermal growth factor in perforating keratoplasty. Ger J Ophthalmol 1996, 5:268-274.
39. Polgar J., Hidasi V., Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem J 1990, 267:557-560.
40. Muszbek L., Polgar J., Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993, 69:282-285.
41. Muszbek L., Haramura G., Polgar J. Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost 1995, 73:702-705.
42. Uotila M.H., Soble R.E., Savory J. Measurement of tear calcium levels. Investig Ophthalmol 1972, 11:258-259.
43. Bagoly Z., Fazakas F., Komaromi I., Haramura G., Toth E., Muszbek L. Cleavage of factor XIII by human neutrophil elastase results in a novel active truncated form of factor XIII A subunit. Thromb Haemost 2008, 99:668-674.